Series A · Biotech · Stockholm, Sweden · Founded 2020 · 11–50 employees
One-carbon Therapeutics is a clinical-stage biotechnology company pioneering first-in-class cancer therapies targeting the one-carbon metabolic pathway. Their lead compound TH9619 is a dual inhibitor of MTHFD1/2 enzymes designed to exploit cancer-specific metabolism while sparing healthy tissue. The company recently completed an oversubscribed 153 million SEK ($16.2 million USD) funding round in December 2025 and successfully transitioned to clinical stage by dosing the first patient in their Phase 1/2 ODIN study. The trial is being conducted across multiple European sites targeting difficult-to-treat refractory solid tumors.
No open roles listed right now.